First Quadrant’s NeoGenomics NEO Stock Holding History

First Quadrant’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5,164	Closed	-$65K	–	773
2018 Q4	$65K	Buy	+5,164	New	+$77K	0.01%	706

Other funds holding NEO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

First Quadrant's NEO Position: Q1 2019 in Review

First Quadrant sold out of NeoGenomics (NEO) in Q1 2019, closing a stake of 5,164 shares — an estimated $65K sold.

First Quadrant first reported a position in NEO in Q4 2018 and held it in 1 quarter. The position peaked at $65K in Q4 2018. 235 funds tracked by Wall St. Rank hold NEO as of Q1 2019.

First Quadrant reported no remaining NeoGenomics position as of Q1 2019 after selling out during the quarter.
First Quadrant sold 5,164 NeoGenomics shares in Q1 2019, an estimated $65K.
First Quadrant first reported a position in NeoGenomics in Q4 2018 and held it in 1 quarter.
First Quadrant's NeoGenomics position peaked at $65K in Q4 2018.
235 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2019.

Based on First Quadrant's 13F filing for Q1 2019, filed 24 Apr 2019.